The Board of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (company) announced that on 15 December 2023, the company and Fosun International Limited entered into the Fosun International Mutual Supply Framework Agreement in relation to the mutual supply of products and provision of services between the Group and Fosun International and/or its associates, for a term of one year commencing from 1 January 2024 to 31 December 2024. Under the Fosun International Mutual Supply Framework Agreement, the products and services to be provided by the Group to Fosun International and/or its associates from time to time during the term thereof mainly include the followings: Products: medical products including medicine, diagnostics and medical devices; and Services: (i) medical services; (ii) medical examination services such as body check and health risk assessment and other related services; (iii) diagnosis testing services; (iv) pharmaceutical industry consulting services; and (v) provision of fund management services to the Connected Subsidiaries of the Company. Under the Fosun International Mutual Supply Framework Agreement, the products and services to be provided by Fosun International and/or its associates to the Group mainly include the followings: Products: the Group may from time to time purchase from Fosun International and/or its associates various types of products including, among others, (i) custom-made products, such as food and beverage, gifts and software; (ii) other products, such as daily necessities, food and beverage, cultural and creative products; and (iii) medical materials provided by the Connected Subsidiaries of the Company.

Services: (i) conferencing services and IT technical support services; (ii) insurance services and insurance brokerage services; (iii) training services; (iv) business travel services; (v) consulting services such as business development; (vi) consultancy services such as fund raising and management; (vii) logistics and freight operation proxy services; (viii) securities and financial services such as brokerage services and investment banking services; and (ix) medical healthcare services provided by the Connected Subsidiaries of the Company. Term: One year from 1 January 2024 to 31 December 2024 (both days inclusive).